MDM2 and leukemia: Dasatinib (D), a pan-tyrosine kinase inhibitor, is an FDA-approved treatment for leukemia [29] while quercetin (Q) targets several anti-apoptotic nodes PI3K [9, 10], HIF-1α [10, 54], and MDM2/p53/p21/serpine (PAI-1 and 2) [9, 10].